Zhejiang Jiuzhou Pharmaceutical News

Jiuzhou Pharmaceutical (603456): Q3 revenue decline narrowed month-on-month, CDMO gross margin remained stable

cscOct 29 17:06

Jiuzhou Pharmaceutical (603456): Q3 performance is under phased pressure to actively promote the layout of new business areas

Open Source SecuritiesOct 26 18:31

Jiuzhou Pharmaceutical (603456): Stable orders from major customers continue to promote overseas layout

China International Capital CorporationOct 26 00:00

Jiuzhou Pharmaceutical (603456) profits are under pressure and awaiting a turning point

htscOct 25 14:56

Jiuzhou Pharmaceutical (603456): The CDMO project pipeline maintains steady growth and needs industry recovery

Aug 29 13:16

Jiuzhou Pharmaceutical (603456): CDMO pipelines are becoming more and more abundant to create a platform for peptides and coupling

Aug 27 14:46

Jiuzhou Pharmaceutical (603456): Starting from the API business, CDMO has strong strength+extended development of formulations

Aug 4 00:00

Minsheng Securities released a research report on April 25 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) Noxintol's global sales increased rapidly in the first quarter, and CDMO o

Zhitong FinanceApr 25 10:57

Jiuzhou Pharmaceutical (603456) 2023 Report Review: Annual Revenue and Profit Growth Slows Down, CDMO Business Achieves High-Quality Growth

Apr 24 00:00

Jiuzhou Pharmaceutical (603456): CDMO is tough under short-term pressure in the API business

Apr 24 00:00

Jiuzhou Pharmaceutical (603456): Annual revenue and profit growth slowed, CDMO business achieved high-quality growth

Apr 22 20:21

Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved

Zhitong FinanceApr 16 19:09

Jiuzhou Pharmaceutical (603456): CDMO business is growing steadily, APIs are under pressure in the short term

Apr 13 00:00

Jiuzhou Pharmaceutical (603456): CDMO is growing steadily and the API business is under pressure in the short term

Apr 12 07:16

Jiuzhou Pharmaceutical (603456): CDMO business grows steadily and continues to lay out new businesses

Apr 10 18:16

Great Wall Guorui Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) Profitability has increased, putting pressure on the API business; 2)

Zhitong FinanceApr 10 15:40

Minsheng Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) the rapid expansion of CDMO business for APIs and formulations, and a stead

Zhitong FinanceApr 10 11:54

Jiuzhou Pharmaceutical (603456): CDMO's steady growth puts pressure on the API sector

Apr 10 08:12

Jiuzhou Pharmaceutical (603456) Annual Report Review Report: Revenue is basically in line with expectations. The CDMO sector maintains high growth and the project pipeline continues to be rich

Apr 9 20:06

Jiuzhou Pharmaceutical (603456): CDMO is resilient and waits for peak rotation

Apr 9 16:56